ABIVAX

Serial Number 97980683
Registration 7986313
700

Registration Progress

Application Filed
May 9, 2022
Under Examination
Feb 13, 2024
Approved for Publication
Jun 27, 2023
Published for Opposition
Jun 27, 2023
Registered
Oct 14, 2025

Trademark Image

ABIVAX

Basic Information

Serial Number
97980683
Registration Number
7986313
Filing Date
May 9, 2022
Registration Date
October 14, 2025
Published for Opposition
June 27, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 14, 2025
Registration
Registered
Classes
005

Rights Holder

ABIVAX

33
Address
7-11 BOULEVARD HAUSSMANN
PARIS 75009
FR

Ownership History

Abivax SA

Original Applicant
03
Paris FR

Abivax SA

Owner at Publication
03
Paris FR

ABIVAX

New Owner After Publication #1
33
PARIS FR

ABIVAX

Original Registrant
33
PARIS FR

Legal Representation

Attorney
Glenn Gundersen

USPTO Deadlines

Next Deadline
2121 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20251014)
Due Date
October 14, 2031
Grace Period Ends
April 14, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

42 events
Date Code Type Description Documents
Oct 14, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Oct 14, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 25, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Sep 25, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Sep 19, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 18, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Apr 7, 2025 IUAF S USE AMENDMENT FILED Loading...
Apr 7, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Apr 6, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
Sep 18, 2025 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Apr 7, 2025 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Sep 18, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 7, 2025 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Apr 7, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 7, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Oct 4, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 4, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 4, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Oct 4, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 9, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 27, 2024 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Feb 28, 2024 NEWN I NEW NOA TO ISSUE Loading...
Feb 28, 2024 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Feb 23, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 23, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Feb 23, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Feb 13, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 4, 2024 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Loading...
Jul 24, 2023 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED Loading...
Jun 27, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 27, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 7, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 25, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 18, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 17, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 17, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 27, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Feb 27, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Feb 27, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 27, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
May 13, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 12, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of autoimmune, inflammatory, gastrointestinal disease
First Use Anywhere: Oct 3, 2024
First Use in Commerce: Oct 8, 2024

Classification

International Classes
005